Form 4: Minerva Neurosciences Director Receives Stock Options

Director Inderjit Kaul was granted 50,000 stock options in Minerva Neurosciences, Inc. as part of a standard equity compensation package.

Summary

• Director Inderjit Kaul acquired 50,000 stock options in Minerva Neurosciences, Inc. (NERV).
• The options have an exercise price of $4.68 per share.
• The grant date for these options is June 3, 2026.
• The options are set to expire on June 2, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential future dilution of existing shareholders upon the exercise of these options.

Risks

• Market volatility affecting the value of the underlying common stock relative to the $4.68 exercise price.

Future Outlook

The options vest in four equal quarterly installments starting three months after June 3, 2026, contingent upon continued service as a non-employee director.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practices in the biotechnology sector to incentivize board members and align their interests with long-term company performance.

Comparison to Industry Standards

• The use of quarterly vesting schedules over one year is consistent with standard director compensation practices for small-cap biotech firms.
• The 10-year expiration term is a standard industry benchmark for executive and director stock option plans.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of the first 1/4 of the options on September 3, 2026.

Key Dates

Keywords

Minerva Neurosciences, NERV, Form 4, Director Compensation, Stock Options, Insider Trading